Working… Menu

123I-MIBG Scintigraphy in Patients Being Evaluated for Neuroendocrine Tumors

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT01373736
Recruitment Status : Unknown
Verified June 2011 by Vancouver Coastal Health.
Recruitment status was:  Not yet recruiting
First Posted : June 15, 2011
Last Update Posted : June 15, 2011
Information provided by:
Vancouver Coastal Health

Brief Summary:
The study is designed to study the safety and effectiveness of 123I-MIBG as a diagnostic imaging agent in evaluating patients with known or suspected neuroendocrine tumors.

Condition or disease Intervention/treatment Phase
Pheochromocytoma Neuroblastoma Paraganglioma Medullary Thyroid Carcinoma Carcinoid Tumors Drug: 123I-meta-iodobenzylguanidine Phase 3

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Primary Purpose: Diagnostic

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   Child, Adult, Older Adult
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Subjects must have a clinical indication for 123I-MIBG imaging to evaluate for the presence, extent, or status of neuroendocrine tumors;
  • subjects must be able and willing to comply with study procedures.

Exclusion Criteria:

  • Subjects with history of renal insufficiency (serum creatinine level > 3.0 mg/dL [265 µmol/L]) and inability to be withdrawn from medications known to interfere with 123I-MIBG uptake;
  • Subjects unable to tolerate lying supine;
  • Subjects pregnant or breastfeeding, unless the information to be gained outweighs the possible hazardous effects of 123I-MIBG administration. Where the assessment of the risk/benefit ration suggests the use of 123I-MIBG in nursing mothers, the breastfeeding should be discontinued for at least 48 hours post-injection.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT01373736

Layout table for location contacts
Contact: Daniel Worsley, MD 604-875-4629

Layout table for location information
Canada, British Columbia
Vancouver Coastal Health
Vancouver, British Columbia, Canada, V5Z1M9
Sponsors and Collaborators
Vancouver Coastal Health
Layout table for investigator information
Principal Investigator: Daniel Worsley, MD Vancouver Coastal Health
Layout table for additonal information
Responsible Party: Daniel Worsley, Vancouver Coastal Health Identifier: NCT01373736    
Other Study ID Numbers: H10-02695
First Posted: June 15, 2011    Key Record Dates
Last Update Posted: June 15, 2011
Last Verified: June 2011
Additional relevant MeSH terms:
Layout table for MeSH terms
Carcinoid Tumor
Thyroid Neoplasms
Neuroectodermal Tumors, Primitive, Peripheral
Neuroectodermal Tumors, Primitive
Neoplasms, Neuroepithelial
Neuroectodermal Tumors
Neoplasms, Germ Cell and Embryonal
Neoplasms by Histologic Type
Neoplasms, Glandular and Epithelial
Neoplasms, Nerve Tissue
Neuroendocrine Tumors
Endocrine Gland Neoplasms
Neoplasms by Site
Head and Neck Neoplasms
Endocrine System Diseases
Thyroid Diseases
Antineoplastic Agents
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action